sintilimab,IBI939
innovent biologics,eli lilly
['sintilimab', 'nsclc', 'sclc', '$ivbxf', 'innovent']
$ivbxf innovent updates phase 1b data of ibi939 (anti-tigit monoclonal antibody) combined with sintilimab in previously untreated pd-l1-selected nsclc at the 2023 asco annual meeting 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities